These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 38897489)

  • 1. Laronidase-loaded liposomes reach the brain and other hard-to-treat organs after noninvasive nasal administration.
    Schuh RS; Franceschi EP; Brum BB; Fachel FNS; Poletto É; Vera LNP; Santos HS; Medeiros-Neves B; Monteagudo de Barros V; Helena da Rosa Paz A; Baldo G; Matte U; Giugliani R; Ferreira Teixeira H
    Int J Pharm; 2024 Jul; 660():124355. PubMed ID: 38897489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose enzyme replacement therapy in murine Hurler syndrome.
    Ou L; Herzog T; Koniar BL; Gunther R; Whitley CB
    Mol Genet Metab; 2014 Feb; 111(2):116-22. PubMed ID: 24100243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transcranial pulsed ultrasound facilitates brain uptake of laronidase in enzyme replacement therapy for Mucopolysaccharidosis type I disease.
    Hsu YH; Liu RS; Lin WL; Yuh YS; Lin SP; Wong TT
    Orphanet J Rare Dis; 2017 Jun; 12(1):109. PubMed ID: 28595620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo genome editing of mucopolysaccharidosis I mice using the CRISPR/Cas9 system.
    Schuh RS; Poletto É; Pasqualim G; Tavares AMV; Meyer FS; Gonzalez EA; Giugliani R; Matte U; Teixeira HF; Baldo G
    J Control Release; 2018 Oct; 288():23-33. PubMed ID: 30170069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of a Combination Therapy with Laronidase and Genistein in Treating Mucopolysaccharidosis Type I in a Mouse Model.
    Malinowska M; Nowicka W; Kloska A; Węgrzyn G; Jakóbkiewicz-Banecka J
    Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38397051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enzyme replacement therapy started at birth improves outcome in difficult-to-treat organs in mucopolysaccharidosis I mice.
    Baldo G; Mayer FQ; Martinelli BZ; de Carvalho TG; Meyer FS; de Oliveira PG; Meurer L; Tavares A; Matte U; Giugliani R
    Mol Genet Metab; 2013 May; 109(1):33-40. PubMed ID: 23562162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enzyme replacement therapy with laronidase (Aldurazyme(®)) for treating mucopolysaccharidosis type I.
    Jameson E; Jones S; Remmington T
    Cochrane Database Syst Rev; 2016 Apr; 4():CD009354. PubMed ID: 27033167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enzyme replacement therapy with laronidase (Aldurazyme(®)) for treating mucopolysaccharidosis type I.
    Jameson E; Jones S; Wraith JE
    Cochrane Database Syst Rev; 2013 Nov; (11):CD009354. PubMed ID: 24257962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enzyme replacement therapy with laronidase (Aldurazyme) for treating mucopolysaccharidosis type I.
    Jameson E; Jones S; Wraith JE
    Cochrane Database Syst Rev; 2013 Sep; (9):CD009354. PubMed ID: 24085657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brain and visceral gene editing of mucopolysaccharidosis I mice by nasal delivery of the CRISPR/Cas9 system.
    Vera LNP; Schuh RS; Fachel FNS; Poletto E; Piovesan E; Kubaski F; Couto E; Brum B; Rodrigues G; Souza H; Giugliani R; Matte U; Baldo G; Teixeira HF
    J Gene Med; 2022 Apr; 24(4):e3410. PubMed ID: 35032067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in hair morphology of mucopolysaccharidosis I patients treated with recombinant human alpha-L-iduronidase (laronidase, Aldurazyme).
    Kloska A; Bohdanowicz J; Konopa G; Tylki-Szymńska A; Jakóbkiewicz-Banecka J; Czartoryska B; Liberek A; Wegrzyn A; Wegrzyn G
    Am J Med Genet A; 2005 Dec; 139(3):199-203. PubMed ID: 16283671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of enzyme replacement therapy started late in a murine model of mucopolysaccharidosis type I.
    Pasqualim G; Baldo G; de Carvalho TG; Tavares AM; Giugliani R; Matte U
    PLoS One; 2015; 10(2):e0117271. PubMed ID: 25646802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anthropometric data of 14 patients with mucopolysaccharidosis I: retrospective analysis and efficacy of recombinant human alpha-L-iduronidase (laronidase).
    Tylki-Szymanska A; Rozdzynska A; Jurecka A; Marucha J; Czartoryska B
    Mol Genet Metab; 2010 Jan; 99(1):10-7. PubMed ID: 19783188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alternative laronidase dose regimen for patients with mucopolysaccharidosis I: a multinational, retrospective, chart review case series.
    Horovitz DD; Acosta AX; Giugliani R; Hlavatá A; Hlavatá K; Tchan MC; Lopes Barth A; Cardoso L; Embiruçu de Araújo Leão EK; Esposito AC; Kyosen SO; De Souza CF; Martins AM
    Orphanet J Rare Dis; 2016 Apr; 11(1):51. PubMed ID: 27129473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of anti-laronidase antibodies on efficacy and safety of laronidase enzyme replacement therapy for MPS I: A comprehensive meta-analysis of pooled data from multiple studies.
    Xue Y; Richards SM; Mahmood A; Cox GF
    Mol Genet Metab; 2016 Apr; 117(4):419-26. PubMed ID: 26920513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mucopolysaccharidosis type I.
    Wraith JE; Jones S
    Pediatr Endocrinol Rev; 2014 Sep; 12 Suppl 1():102-6. PubMed ID: 25345091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of laronidase therapy in patients with mucopolysaccharidosis type I who initiated enzyme replacement therapy in adult age. A systematic review and meta-analysis.
    Pérez-López J; Morales-Conejo M; López-Rodríguez M; Hermida-Ameijeiras Á; Moltó-Abad M
    Mol Genet Metab; 2017 Jun; 121(2):138-149. PubMed ID: 28410878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel approach to idursulfase and laronidase desensitization in type 2 and type 1 S mucopolysaccharidosis (MPS).
    Spataro F; Viggiani F; Macchia DG; Rollo V; Tummolo A; Suppressa P; Sabba' C; Rossi MP; Giliberti L; Satriano F; Nettis E; Di Bona D; Caiaffa MF; Fischetto R; Macchia L
    Orphanet J Rare Dis; 2022 Nov; 17(1):402. PubMed ID: 36329518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Laronidase-functionalized multiple-wall lipid-core nanocapsules: promising formulation for a more effective treatment of mucopolysaccharidosis type I.
    Mayer FQ; Adorne MD; Bender EA; de Carvalho TG; Dilda AC; Beck RC; Guterres SS; Giugliani R; Matte U; Pohlmann AR
    Pharm Res; 2015 Mar; 32(3):941-54. PubMed ID: 25208876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lysosomal enzyme can bypass the blood-brain barrier and reach the CNS following intranasal administration.
    Wolf DA; Hanson LR; Aronovich EL; Nan Z; Low WC; Frey WH; McIvor RS
    Mol Genet Metab; 2012 May; 106(1):131-4. PubMed ID: 22420937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.